These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25076343)

  • 1. Pancreatic cancer: new hopes for early detection and a future screening tool?
    El-Jurdi NH; Saif MW
    JOP; 2014 Jul; 15(4):358-9. PubMed ID: 25076343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of a potential biomarker for early-stage pancreatic cancer.
    Topilow AA; Davis JM; Vernick JJ; Tang D; Corbett S; Veltman T; Wagner SJ; Gilvarg C
    Cancer Biomark; 2011-2012; 10(1):27-33. PubMed ID: 22297549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer.
    Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY
    Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
    Zhang Y; Ji SR; Feng DX; Ji J; Han TQ
    Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
    Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
    Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
    Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
    Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying markers for pancreatic cancer by gene expression analysis.
    Zhou W; Sokoll LJ; Bruzek DJ; Zhang L; Velculescu VE; Goldin SB; Hruban RH; Kern SE; Hamilton SR; Chan DW; Vogelstein B; Kinzler KW
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Bussom S; Saif MW
    JOP; 2010 Mar; 11(2):128-30. PubMed ID: 20208319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA 19-9 and pancreatic carcinoma, a revival?
    Ducreux M; Boige V; Malka D
    Onkologie; 2007 Feb; 30(1-2):12-3. PubMed ID: 17264520
    [No Abstract]   [Full Text] [Related]  

  • 15. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
    Fong ZV; Winter JM
    Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer.
    Go VL
    Pancreas; 1994 Nov; 9(6):673. PubMed ID: 7846009
    [No Abstract]   [Full Text] [Related]  

  • 17. Is CA 19-9 useful in the management of pancreatic cancer?
    Balzano G; Di Carlo V
    Lancet Oncol; 2008 Feb; 9(2):89-91. PubMed ID: 18237847
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer.
    Wu Z; Kuntz AI; Wadleigh RG
    Clin Adv Hematol Oncol; 2013 Jan; 11(1):50-2. PubMed ID: 23416865
    [No Abstract]   [Full Text] [Related]  

  • 20. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.